Review



nucleospin mirna  (TaKaRa)


Bioz Verified Symbol TaKaRa is a verified supplier
Bioz Manufacturer Symbol TaKaRa manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    TaKaRa nucleospin mirna
    Nucleospin Mirna, supplied by TaKaRa, used in various techniques. Bioz Stars score: 95/100, based on 86 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nucleospin+mirna/NucleoSpin+miRNA/us12630881-229-9-11
    Average 95 stars, based on 86 article reviews
    nucleospin mirna - by Bioz Stars, 2026-10
    95/100 stars

    Images

    Related Articles

    RNA Extraction:

    Article Title: Comparison of miRNAs and mRNA in bovine follicular fluid and granulosa cells
    Article Snippet: .. RNA extraction was performed using NucleoSpin® miRNA (Takara, Kyoto, Japan) according to the manufacturer’s instructions. ..

    Purification:

    Article Title: Synthetic short mRNA prevents metastasis via innate-adaptive immunity.
    Article Snippet: .. The precipitate was further purified using NucleoSpin miRNA (Takara), and the purified small RNA fraction was analyzed on a 16% ureapolyacrylamide gel. ..

    Article Title: Synthetic short mRNA prevents metastasis via innate-adaptive immunity
    Article Snippet: .. The precipitate was further purified using NucleoSpin miRNA (Takara), and the purified small RNA fraction was analyzed on a 16% urea-polyacrylamide gel. ..

    Transfection:

    Article Title: Broccoli-derived nanovesicles inhibited LPS-induced inflammatory response in mouse macrophage RAW264 cells.
    Article Snippet: O R IG IN A L U N E D IT E D M A N U S C R IP T 28 We prepared nanovesicles (NVs) derived from broccoli using ultracentrifugation and evaluated their 29 anti-inflammatory properties.. Two distinct NV populations were isolated as precipitates from broccoli 30 homogenates following centrifugation at 20,000 × g and 200,000 × g. These NVs contained RNAs, 31 proteins, isothiocyanates, and chlorophylls.. Dynamic light scattering analysis confirmed their 32 nanoscale size.

    Isolation:

    Article Title: Broccoli-derived nanovesicles inhibited LPS-induced inflammatory response in mouse macrophage RAW264 cells.
    Article Snippet: O R IG IN A L U N E D IT E D M A N U S C R IP T 28 We prepared nanovesicles (NVs) derived from broccoli using ultracentrifugation and evaluated their 29 anti-inflammatory properties.. Two distinct NV populations were isolated as precipitates from broccoli 30 homogenates following centrifugation at 20,000 × g and 200,000 × g. These NVs contained RNAs, 31 proteins, isothiocyanates, and chlorophylls.. Dynamic light scattering analysis confirmed their 32 nanoscale size.

    Article Title: Tofogliflozin attenuates renal lipid deposition and inflammation via PPARα upregulation mediated by miR-21a impairment in diet-induced steatohepatitic mice
    Article Snippet: Transmission electron microscopy (TEM) was performed using HT7800 (Hitachi High-Tech, Tokyo, Japan), and assessed number of lipid droplets (LDs). .. Total RNA was isolated from the renal cortex tissues using the RNeasy Mini Kit (Cat.No.74106, QIAGEN, Hilden, Germany) or NucleoSpin miRNA (Cat.No.740971, Takara Bio, Shiga, Japan). .. RNA was reverse transcribed using the SuperScript VILO cDNA Synthesis Kit (Cat.No.11754, Termo Fisher Scientific, MA, USA) or the Mir-X miRNA First-Strand Synthesis Kit (Cat.No.638313, Takara Bio, Shiga, Japan).

    Formalin-fixed Paraffin-Embedded:

    Article Title: miR‑100‑5p and miR‑203a‑3p suppress esophageal squamous cell carcinoma progression by targeting FKBP5.
    Article Snippet: .. FFPE tissue samples were cut into 10‐μm‐thick sections, and total RNA was extracted using the miRNeasy FFPE kit (Qiagen GmbH) and NucleoSpin miRNA (Takara Bio, Inc.), following the manufacturer's protocols. .. A NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.) was used to measure the total RNA concentration.

    Article Title: miR-100-5p and miR-203a-3p suppress esophageal squamous cell carcinoma progression by targeting FKBP5
    Article Snippet: Densitometric analysis of the protein bands was performed using FIJI (ImageJ; version 1.54q, National Institutes of Health). .. FFPE tissue samples were cut into 10-μm-thick sections, and total RNA was extracted using the miRNeasy FFPE kit (Qiagen GmbH) and NucleoSpin miRNA (Takara Bio, Inc.), following the manufacturer's protocols. .. A NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.) was used to measure the total RNA concentration.



    Similar Products

    nucleospin mirna plasma kit  (MACHEREY NAGEL)
    96
    MACHEREY NAGEL nucleospin mirna plasma kit
    Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma <t>miRNA</t> levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.
    Nucleospin Mirna Plasma Kit, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nucleospin+mirna/NucleoSpin+miRNA%2C+Mini+kit+for+miRNA+and+RNA+purification/pmc13237519-162-10-14
    Average 96 stars, based on 1 article reviews
    nucleospin mirna plasma kit - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    nucleospin mirna  (TaKaRa)
    95
    TaKaRa nucleospin mirna
    Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma <t>miRNA</t> levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.
    Nucleospin Mirna, supplied by TaKaRa, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nucleospin+mirna/NucleoSpin+miRNA/us12630881-229-9-11
    Average 95 stars, based on 1 article reviews
    nucleospin mirna - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    nucleospin mirna kit  (MACHEREY NAGEL)
    96
    MACHEREY NAGEL nucleospin mirna kit
    Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma <t>miRNA</t> levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.
    Nucleospin Mirna Kit, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nucleospin+mirna/NucleoSpin+miRNA%2C+Mini+kit+for+miRNA+and+RNA+purification/pm42143393-70-13-16
    Average 96 stars, based on 1 article reviews
    nucleospin mirna kit - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    nucleospin mirna kit  (TaKaRa)
    95
    TaKaRa nucleospin mirna kit
    circPDE4B interacts with AD‐associated miRNAs. A, Volcano plot of miRNAs enriched in circPDE4B pulldown (log2FC > 1, −log10FDR > 1; checked against miRBase/miRTarBase; n = 5 biological replicate). B, Heatmap of enriched miRNAs with fold change > 4. C, Network analysis of circPDE4B‐interacting miRNAs, predicted target genes, and associated pathways, highlighting neurodegeneration‐related signaling. D, Overlap of circPDE4B‐interacting miRNAs with AD‐associated miRNAs identified in four independent datasets. E, Network analysis of 10 circPDE4B‐interacting miRNAs associated with AD, depicting convergent pathways of neurodegeneration. AD, Alzheimer's disease; <t>miRNA,</t> micro RNA.
    Nucleospin Mirna Kit, supplied by TaKaRa, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nucleospin+mirna/NucleoSpin+miRNA/pmc13137278-146-16-19
    Average 95 stars, based on 1 article reviews
    nucleospin mirna kit - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    rna purification  (MACHEREY NAGEL)
    96
    MACHEREY NAGEL rna purification
    circPDE4B interacts with AD‐associated miRNAs. A, Volcano plot of miRNAs enriched in circPDE4B pulldown (log2FC > 1, −log10FDR > 1; checked against miRBase/miRTarBase; n = 5 biological replicate). B, Heatmap of enriched miRNAs with fold change > 4. C, Network analysis of circPDE4B‐interacting miRNAs, predicted target genes, and associated pathways, highlighting neurodegeneration‐related signaling. D, Overlap of circPDE4B‐interacting miRNAs with AD‐associated miRNAs identified in four independent datasets. E, Network analysis of 10 circPDE4B‐interacting miRNAs associated with AD, depicting convergent pathways of neurodegeneration. AD, Alzheimer's disease; <t>miRNA,</t> micro RNA.
    Rna Purification, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nucleospin+mirna/NucleoSpin+miRNA%2C+Mini+kit+for+miRNA+and+RNA+purification/pmc13082790-193-25-27
    Average 96 stars, based on 1 article reviews
    rna purification - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    nucleospin mirna plasma mini  (MACHEREY NAGEL)
    95
    MACHEREY NAGEL nucleospin mirna plasma mini
    Levels of microRNA <t>(miRNA)</t> 27a (A) , 27b (B) , 181 (C) , and 137 (D) during the first (Base), second (Visit 1), and third (Visit 2) trimesters in patients with preeclampsia (PE) compared to healthy control pregnancies (healthy). Due to the limited number of samples and patient-to-patient variability, data were evaluated for outliers, and statistical significance was assessed using the Kruskal–Wallis ANOVA, without assumptions of normality or lognormality. Only a few predefined comparisons were performed; therefore, no correction for multiple comparisons was applied (see methods).
    Nucleospin Mirna Plasma Mini, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nucleospin+mirna/NucleoSpin+miRNA+Plasma%2C+Mini+kit+for+circulating+miRNA/pmc13078980-87-13-17
    Average 95 stars, based on 1 article reviews
    nucleospin mirna plasma mini - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    nucleospin mirna  (MACHEREY NAGEL)
    96
    MACHEREY NAGEL nucleospin mirna
    Levels of microRNA <t>(miRNA)</t> 27a (A) , 27b (B) , 181 (C) , and 137 (D) during the first (Base), second (Visit 1), and third (Visit 2) trimesters in patients with preeclampsia (PE) compared to healthy control pregnancies (healthy). Due to the limited number of samples and patient-to-patient variability, data were evaluated for outliers, and statistical significance was assessed using the Kruskal–Wallis ANOVA, without assumptions of normality or lognormality. Only a few predefined comparisons were performed; therefore, no correction for multiple comparisons was applied (see methods).
    Nucleospin Mirna, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nucleospin+mirna/NucleoSpin+miRNA%2C+Mini+kit+for+miRNA+and+RNA+purification/pm41593349-81-0-2
    Average 96 stars, based on 1 article reviews
    nucleospin mirna - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma miRNA levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.

    Journal: Oncology Letters

    Article Title: Lectin-captured plasma microRNAs predict response and survival in patients with non-small cell lung cancer treated with nivolumab

    doi: 10.3892/ol.2026.15669

    Figure Lengend Snippet: Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma miRNA levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.

    Article Snippet: After thorough vortex mixing, the miRNA was purified using the NucleoSpin miRNA Plasma kit (Macherey-Nagel, Germany) with DNA digestion treatment, according to the manufacturer's protocol.

    Techniques: Staining, Clinical Proteomics, Purification, Microarray, Biomarker Discovery, Reverse Transcription, MANN-WHITNEY, Real-time Polymerase Chain Reaction

    Differential expression of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with non-small cell lung cancer with PR or SD + PD. (A) Relative levels of miR-320a, miR-320b, and miR-3613-5p without OAA1 enrichment. (B) With OAA1 column enrichment. Plasma miRNA levels were quantified by reverse transcription-quantitative polymerase chain reaction and are shown as relative abundance using the 2 −ΔCq method normalized to miR-16-5p. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miR, microRNA; OAA1, Oscillatoria agardhii agglutinin 1; SD, stable disease; PD, progressive disease; PR, partial response.

    Journal: Oncology Letters

    Article Title: Lectin-captured plasma microRNAs predict response and survival in patients with non-small cell lung cancer treated with nivolumab

    doi: 10.3892/ol.2026.15669

    Figure Lengend Snippet: Differential expression of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with non-small cell lung cancer with PR or SD + PD. (A) Relative levels of miR-320a, miR-320b, and miR-3613-5p without OAA1 enrichment. (B) With OAA1 column enrichment. Plasma miRNA levels were quantified by reverse transcription-quantitative polymerase chain reaction and are shown as relative abundance using the 2 −ΔCq method normalized to miR-16-5p. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miR, microRNA; OAA1, Oscillatoria agardhii agglutinin 1; SD, stable disease; PD, progressive disease; PR, partial response.

    Article Snippet: After thorough vortex mixing, the miRNA was purified using the NucleoSpin miRNA Plasma kit (Macherey-Nagel, Germany) with DNA digestion treatment, according to the manufacturer's protocol.

    Techniques: Quantitative Proteomics, Clinical Proteomics, Reverse Transcription, Real-time Polymerase Chain Reaction, MANN-WHITNEY

    ROC curve analysis of miRNAs for predicting non-response to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer treated with nivolumab. (A) ROC curves for circulating miR-320a, miR-320b, and miR-3613-5p without OAA1 column enrichment. (B) With OAA1 enrichment. AUC, area under the curve; CI, confidence interval; miR, microRNA; OAA1, Oscillatoria agardhii agglutinin 1; ROC, receiver operating characteristic.

    Journal: Oncology Letters

    Article Title: Lectin-captured plasma microRNAs predict response and survival in patients with non-small cell lung cancer treated with nivolumab

    doi: 10.3892/ol.2026.15669

    Figure Lengend Snippet: ROC curve analysis of miRNAs for predicting non-response to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer treated with nivolumab. (A) ROC curves for circulating miR-320a, miR-320b, and miR-3613-5p without OAA1 column enrichment. (B) With OAA1 enrichment. AUC, area under the curve; CI, confidence interval; miR, microRNA; OAA1, Oscillatoria agardhii agglutinin 1; ROC, receiver operating characteristic.

    Article Snippet: After thorough vortex mixing, the miRNA was purified using the NucleoSpin miRNA Plasma kit (Macherey-Nagel, Germany) with DNA digestion treatment, according to the manufacturer's protocol.

    Techniques:

    Kaplan-Meier analysis for OS based on pre-treatment plasma levels of miR-320a, miR-320b, and miR-3613-5p in patients with non-small cell lung cancer treated with nivolumab (n=48). (A) Kaplan-Meier curves comparing the OS between the high- and low-expression groups for each miRNA without OAA1 column enrichment. (B) Kaplan-Meier curves for the same miRNAs with the OAA1 enrichment. The number of patients in each group is indicated in the legends. Cutoff values for high/low expression were determined using receiver operating characteristic analysis. P-values are shown; *P<0.05. miR, microRNA; OAA1, Oscillatoria agardhii agglutinin 1; OS, overall survival.

    Journal: Oncology Letters

    Article Title: Lectin-captured plasma microRNAs predict response and survival in patients with non-small cell lung cancer treated with nivolumab

    doi: 10.3892/ol.2026.15669

    Figure Lengend Snippet: Kaplan-Meier analysis for OS based on pre-treatment plasma levels of miR-320a, miR-320b, and miR-3613-5p in patients with non-small cell lung cancer treated with nivolumab (n=48). (A) Kaplan-Meier curves comparing the OS between the high- and low-expression groups for each miRNA without OAA1 column enrichment. (B) Kaplan-Meier curves for the same miRNAs with the OAA1 enrichment. The number of patients in each group is indicated in the legends. Cutoff values for high/low expression were determined using receiver operating characteristic analysis. P-values are shown; *P<0.05. miR, microRNA; OAA1, Oscillatoria agardhii agglutinin 1; OS, overall survival.

    Article Snippet: After thorough vortex mixing, the miRNA was purified using the NucleoSpin miRNA Plasma kit (Macherey-Nagel, Germany) with DNA digestion treatment, according to the manufacturer's protocol.

    Techniques: Clinical Proteomics, Expressing

    circPDE4B interacts with AD‐associated miRNAs. A, Volcano plot of miRNAs enriched in circPDE4B pulldown (log2FC > 1, −log10FDR > 1; checked against miRBase/miRTarBase; n = 5 biological replicate). B, Heatmap of enriched miRNAs with fold change > 4. C, Network analysis of circPDE4B‐interacting miRNAs, predicted target genes, and associated pathways, highlighting neurodegeneration‐related signaling. D, Overlap of circPDE4B‐interacting miRNAs with AD‐associated miRNAs identified in four independent datasets. E, Network analysis of 10 circPDE4B‐interacting miRNAs associated with AD, depicting convergent pathways of neurodegeneration. AD, Alzheimer's disease; miRNA, micro RNA.

    Journal: Alzheimer's & Dementia

    Article Title: circPDE4B downregulation triggers GEMIN5‑dependent translational stress response and autophagy to reduce MAPT pathology

    doi: 10.1002/alz.71436

    Figure Lengend Snippet: circPDE4B interacts with AD‐associated miRNAs. A, Volcano plot of miRNAs enriched in circPDE4B pulldown (log2FC > 1, −log10FDR > 1; checked against miRBase/miRTarBase; n = 5 biological replicate). B, Heatmap of enriched miRNAs with fold change > 4. C, Network analysis of circPDE4B‐interacting miRNAs, predicted target genes, and associated pathways, highlighting neurodegeneration‐related signaling. D, Overlap of circPDE4B‐interacting miRNAs with AD‐associated miRNAs identified in four independent datasets. E, Network analysis of 10 circPDE4B‐interacting miRNAs associated with AD, depicting convergent pathways of neurodegeneration. AD, Alzheimer's disease; miRNA, micro RNA.

    Article Snippet: The aqueous phase was carefully collected, and total RNA (including small RNAs/miRNAs) was purified using the NucleoSpin miRNA kit (Takara Bio USA, Cat# 740971.250) according to the manufacturer's protocol.

    Techniques:

    Levels of microRNA (miRNA) 27a (A) , 27b (B) , 181 (C) , and 137 (D) during the first (Base), second (Visit 1), and third (Visit 2) trimesters in patients with preeclampsia (PE) compared to healthy control pregnancies (healthy). Due to the limited number of samples and patient-to-patient variability, data were evaluated for outliers, and statistical significance was assessed using the Kruskal–Wallis ANOVA, without assumptions of normality or lognormality. Only a few predefined comparisons were performed; therefore, no correction for multiple comparisons was applied (see methods).

    Journal: Frontiers in Cardiovascular Medicine

    Article Title: Cell-free mitochondrial DNA and microRNA-137 for early diagnosis of preeclampsia

    doi: 10.3389/fcvm.2026.1778221

    Figure Lengend Snippet: Levels of microRNA (miRNA) 27a (A) , 27b (B) , 181 (C) , and 137 (D) during the first (Base), second (Visit 1), and third (Visit 2) trimesters in patients with preeclampsia (PE) compared to healthy control pregnancies (healthy). Due to the limited number of samples and patient-to-patient variability, data were evaluated for outliers, and statistical significance was assessed using the Kruskal–Wallis ANOVA, without assumptions of normality or lognormality. Only a few predefined comparisons were performed; therefore, no correction for multiple comparisons was applied (see methods).

    Article Snippet: Circulating miRNAs were extracted from 350 μL of plasma using the commercial kit NucleoSpin miRNA Plasma Mini (Macherey-Nagel) as per the manufacturer's instructions and eluted in 30 μL of nuclease-free water. miRNAs were retro-transcribed and pre-amplified with TaqMan, advanced miRNA cDNA Synthesis Kit (Applied Biosystems) following the manufacturer's instructions (2 μL of input RNA, 14 cycles of PCR preamplification).

    Techniques: Control